Financial Performance - Net profit attributable to shareholders increased by 6.33% year-over-year, amounting to CNY 78,821,896.76[6] - The company reported a significant increase in investment income, which rose by 929.25% to 2,731,196.59 RMB, primarily due to increased interest income from structured deposits[16] - The company reported a net cash flow from operating activities of 86,452,497.93 RMB, a 43.82% increase compared to the same period in 2019, mainly due to government subsidies related to assets[16] - The company’s net profit for the first three quarters of 2020 reached ¥78,099,968.15, compared to ¥75,416,494.97 in the same period of 2019, showing a growth of about 3.4%[38] - The total profit for Q3 2020 was ¥37,770,191.09, compared to ¥29,793,754.80 in Q3 2019, indicating a year-over-year increase of approximately 26.5%[37] Assets and Liabilities - Total assets increased by 189.76% year-over-year, reaching CNY 1,725,875,235.31[6] - Total liabilities reached CNY 200,443,944.90, up from CNY 125,158,317.20, showing an increase of about 60%[23] - The total assets as of Q3 2020 amounted to ¥1,730,301,751.55, compared to ¥592,720,170.48 in the previous year, showing a significant increase[28] - Total liabilities for Q3 2020 were ¥228,106,395.36, up from ¥144,647,259.63 in Q3 2019, which is an increase of about 57.7%[28] - The company's long-term deferred expenses rose by 104.53% to 4,580,040.69 RMB, driven by increased costs for technical renovations and drug re-registration fees[15] Shareholder Information - Net assets attributable to shareholders rose by 227.46% compared to the previous year, totaling CNY 1,518,587,187.58[6] - The total number of shareholders at the end of the reporting period was 12,444[11] - Shareholders' equity rose to CNY 1,525,431,290.41 from CNY 470,462,545.73, representing a growth of approximately 224%[24] - The total equity attributable to shareholders was ¥463,742,813.63[47] Revenue and Expenses - Operating income for the first nine months remained stable at CNY 402,963,858.69, showing a 0.00% change year-over-year[6] - Total operating revenue for Q3 2020 reached ¥159,892,223.39, an increase from ¥146,939,257.53 in Q3 2019, representing an increase of approximately 8.3%[31] - Total operating costs for Q3 2020 were ¥122,870,951.77, compared to ¥118,545,451.87 in Q3 2019, reflecting an increase of about 2.8%[31] - Research and development expenses accounted for 5.82% of operating income, up by 0.13 percentage points from the previous year[6] - Research and development expenses for Q3 2020 were ¥7,102,847.76, a decrease from ¥12,082,979.08 in Q3 2019, indicating a reduction of about 41.5%[32] Cash Flow - The net cash flow from operating activities for the third quarter of 2020 was CNY 86,452,497.93, up from CNY 60,112,002.08 in Q3 2019, representing a year-over-year increase of approximately 43%[40] - The company raised CNY 1,038,274,635.43 from financing activities in the first three quarters of 2020, with a net cash flow from financing activities of CNY 1,027,240,536.66, a significant improvement from negative cash flow in the previous year[43] - The ending cash and cash equivalents balance for the third quarter of 2020 was CNY 182,835,395.71, compared to CNY 116,546,566.95 at the end of Q3 2019, reflecting a year-over-year increase of approximately 56.7%[41] Changes in Financial Position - The weighted average return on equity decreased by 10.87 percentage points to 8.24%[6] - Basic earnings per share decreased by 7.55% to CNY 0.49[6] - The company has not indicated any significant changes in its profit forecast for the upcoming reporting period[18] - The company implemented a new revenue accounting standard starting January 1, 2020, affecting financial reporting[48]

Financial Performance - The company's operating revenue for the first half of 2020 was approximately RMB 243.07 million, a decrease of 5.06% compared to RMB 256.02 million in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2020 was approximately RMB 45.50 million, down 6.27% from RMB 48.55 million in the previous year[21]. - The basic earnings per share for the first half of 2020 was RMB 0.31, a decrease of 11.43% compared to RMB 0.35 in the same period last year[21]. - The company's net assets attributable to shareholders increased by 229.95% to approximately RMB 1.53 billion from RMB 463.74 million at the end of the previous year[21]. - Total assets increased by 177.60% to approximately RMB 1.65 billion from RMB 595.62 million at the end of the previous year[21]. - The company's R&D investment as a percentage of operating revenue increased to 6.73%, up 2.50 percentage points from 4.23% in the same period last year[21]. - The net cash flow from operating activities for the first half of 2020 was approximately RMB 43.12 million, an increase of 2.77% compared to RMB 41.95 million in the previous year[21]. - The diluted earnings per share for the first half of 2020 was also RMB 0.31, reflecting the same decrease of 11.43% compared to the previous year[21]. - The company reported a net profit of approximately RMB 45.07 million after deducting non-recurring gains and losses, a decrease of 3.63% from RMB 46.77 million in the same period last year[21]. - The weighted average return on net assets decreased by 6.01 percentage points to 6.93% compared to 12.94% in the same period last year[21]. Corporate Governance - The board of directors confirmed that the financial report is true, accurate, and complete, ensuring accountability for any misrepresentation[5]. - The board meeting was attended by all directors, indicating a unified approach to governance[4]. - The company does not have any special arrangements for corporate governance[6]. - The company has a robust governance structure in place, enhancing internal control and risk management across key operational areas[78]. - The company has committed to addressing any potential conflicts of interest and related party transactions[98]. Risk Management - The report emphasizes the importance of risk factors in the company's operations, urging investors to be aware of potential investment risks[3]. - The company has outlined various risks faced during production and operations in the report[3]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a commitment to investors[6]. - The half-year report has not been audited, which may affect the reliability of the financial data presented[4]. - The company is facing risks from national drug procurement policies that may lead to significant price reductions for its main products[79]. - The company faces risks related to the approval of new drug applications, which may not meet expectations due to stringent regulatory requirements[83]. Research and Development - The company has established a comprehensive drug research and development system supported by a new drug R&D technology platform, focusing on compound formulations, deuterated drugs, and liposome drugs[32]. - The company has increased R&D investment, focusing on innovative drug development, including JJH201501 (an antidepressant) which is currently in Phase II clinical trials[75]. - The total R&D investment for the reporting period was ¥16,362,354.21, representing 6.73% of total revenue[52]. - The company has developed advanced liposome technology, significantly improving drug encapsulation rates and therapeutic efficacy[48][54]. - The company is focusing on expanding its R&D in antidepressants and antitumor drugs, with ongoing projects in various stages of development[49]. Product Portfolio - The company is a national high-tech enterprise specializing in drug research, production, and sales, focusing on innovative drugs for diseases such as depression, tumors, and gastric diseases[26]. - The main products include tablets, capsules, and eye drops, with key products being Likujun tablets and Niqunlor tablets, both included in the National Basic Medical Insurance Directory[27][28]. - Likujun tablets are the only product in the market for treating leukopenia and have been widely sold in thousands of hospitals across China[27]. - Niqunlor tablets are the first compound antihypertensive drug in China, recommended in multiple hypertension treatment guidelines, and are exclusively produced by the company[28]. - The company’s capsule products include Yipingfeng capsules and Yiganling capsules, both of which are included in the National Basic Medical Insurance Directory[30]. - The eye drop products include Gatifloxacin eye drops and Lomefloxacin hydrochloride eye drops, both of which are classified as national second-class new drugs[31]. Market and Financial Position - The global pharmaceutical market is projected to grow from $1.13 trillion in 2016 to $1.5 trillion by 2021, with a compound annual growth rate (CAGR) of 4% to 7%[39]. - By 2020, China's pharmaceutical market is expected to account for 11% of the global market, while the U.S. will hold 42%[39]. - The company reported a total revenue of 77,925,000 RMB for the first half of 2020, with a gross profit of 9,300,250 RMB, indicating a gross margin of approximately 11.94%[55]. - Cash and cash equivalents increased by 125.58% to 436,235,221 RMB as of June 30, 2020, primarily due to funds raised from the initial public offering[59]. - The company has established a comprehensive marketing network covering 16 regions and 56 offices, effectively reaching thousands of hospitals across the country[63]. Shareholder and Dividend Information - The company plans to distribute a cash dividend of RMB 2.40 per 10 shares, totaling RMB 44,865,984.00 based on a total share capital of 186,941,600 shares[5]. - The company has committed to a profit distribution policy to protect shareholder interests, adhering to the regulations set forth in the "Three-Year Dividend Return Plan" after its IPO[122]. - The company has committed to not reducing its shareholdings during the lock-up period of 36 months post-IPO, during which major shareholders cannot transfer their shares[99]. Compliance and Legal Matters - The company has ensured compliance with all legal and regulatory requirements regarding shareholder meetings and resolutions[95]. - The company has maintained a good integrity status, fulfilling its duties diligently and honestly according to relevant laws and regulations[129]. - There are no significant litigation or arbitration matters reported during the reporting period[129]. - The financial statements were approved by the board on August 25, 2020, ensuring compliance with regulatory standards[199].